Open AccessAssessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
Author(s) -
Antonio Pardo,
Thomas King,
Eman Rafla,
Judith C. Kando
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s309378
Subject(s) - aftertaste , palatability , stimulant , taste , amphetamine , medicine , psychology , psychiatry , pathology , neuroscience , dopamine
ADHD is, for many people, a lifelong disease that requires chronic medication use. Stimulant therapy is often recommended as first-line treatment for ADHD. Adherence to stimulant treatment among patients diagnosed with ADHD is poor. Major regulatory agencies have recommended measurement of palatability for new tablet formulations. A new amphetamine extended-release tablet (AMPH ER TAB) for the treatment of attention-deficit/hyperactivity disorder (ADHD) was developed. The AMPH ER TAB has a bubblegum flavor and can be chewed or swallowed whole. In 2016, the FDA developed a draft guidance document on the topic of chewable drug tablet formulation palatability.